This announcement is a separate document:
アステラス製薬：VYLOY（ゾルベツキシマブ（遺伝子組換え）） 局所進行性または転移性胃腺がん および食道胃接合部腺がんの治療薬として米国で承認取得
Astellas Pharma: VYLOY (zolbetuximab (genetically modified)) approved in the US for the treatment of locally advanced or metastatic gastric adenocarcinoma and esophagogastric junction adenocarcinoma
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated